{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:27:35Z","timestamp":1787246855569,"version":"build-2736575974"},"reference-count":28,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"unspecified","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R211HL170269"],"award-info":[{"award-number":["1R211HL170269"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["bmjmed"],"accepted":{"date-parts":[[2026,7,3]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the clinical effectiveness of sodium glucose cotransporter 2 (SGLT2) inhibitors in reducing the risk of hospital admission for heart failure and mortality in a contemporary nationwide cohort of patients with heart failure with preserved ejection fraction (HFpEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Nationwide cohort study (REFINE-HFpEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>170 veteran health medical centres across the US, 1 January 2014 to 31 December 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>2177 patients with type 2 diabetes and HFpEF; 1129 patients were newly prescribed SGLT2 inhibitors and 1048 were newly prescribed dipeptidyl peptidase 4 (DPP4) inhibitors or sulfonylureas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>The primary outcome was a composite of all cause mortality and hospital admission for heart failure. Secondary outcomes included all cause mortality only and serial changes in body weight. Hazard ratios were derived from Cox proportional hazards models, incorporating inverse probability of treatment weighting based on propensity scores to account for confounding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From a validated cohort of 179 288 patients with type 2 diabetes and HFpEF, the study included 1129 new users of SGLT2 inhibitors (active treatment) and 1048 new users of DPP4 inhibitors or sulfonylureas (comparators). After a median follow-up of 2.63 years, 46.4% of the study population had at least one hospital admission for heart failure (n=1011) and the overall mortality rate was 45.9% (n=1000). Use of SGLT2 inhibitors was associated with a relative risk reduction in the primary composite outcome of 18% compared with the use of DPP4 inhibitors or sulfonylureas (hazard ratio 0.82, 95% confidence interval 0.70 to 0.96; P=0.01). The adjusted hazard ratio for all cause mortality only was 0.73 (0.60 to 0.89; P=0.002). Weight loss was similar in the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large, contemporary, nationwide cohort of patients with HFpEF, type 2 diabetes, and high event rates, starting SGLT2 inhibitors was associated with a significantly lower risk of hospital admission for heart failure and all cause mortality compared with starting treatment with DPP4 inhibitors or sulfonylureas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjmed-2025-002380","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:50:18Z","timestamp":1787244618000},"page":"e002380","source":"Crossref","is-referenced-by-count":0,"title":["Clinical effectiveness of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: nationwide cohort study (REFINE-HFpEF)"],"prefix":"10.1136","volume":"5","author":[{"given":"Padmini","family":"Selvaganesan","sequence":"first","affiliation":[{"name":"Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"Department of Cardiology, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Karnib","sequence":"additional","affiliation":[{"name":"Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"Department of Cardiology, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7805-0654","authenticated-orcid":false,"given":"Irfan","family":"Helmy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"Department of Medicine, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh N V","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Osman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"Department of Cardiology, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA"},{"name":"Department of Cardiology, University Hospitals Harrington Heart and Vascular Institute, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayakumar","family":"Sahadevan","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, Cleveland, Ohio, USA"},{"name":"Louis Stokes VA Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosita","family":"Zakeri","sequence":"additional","affiliation":[{"name":"British Heart Foundation Centre for Research Excellence, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6543-8482","authenticated-orcid":false,"given":"Varun","family":"Sundaram","sequence":"additional","affiliation":[{"name":"Department of Medicine, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA"},{"name":"Department of Cardiology, University Hospitals Harrington Heart and Vascular Institute, Cleveland, Ohio, USA"},{"name":"Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"},{"name":"Health Services Research Center, University Hospitals Research & Education Institute, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2026082009500911000_5.1.e002380.1","doi-asserted-by":"crossref","DOI":"10.1186\/s12877-024-04771-2","article-title":"Reasons for hospitalisation and cumulative mortality in people, 75 years or older, at high risk of hospital admission: a prospective study","volume":"24","author":"Lundgren","year":"2024","journal-title":"BMC Geriatr"},{"key":"2026082009500911000_5.1.e002380.2","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000001063"},{"key":"2026082009500911000_5.1.e002380.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.03.006"},{"key":"2026082009500911000_5.1.e002380.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038"},{"key":"2026082009500911000_5.1.e002380.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286"},{"key":"2026082009500911000_5.1.e002380.6","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.cardfail.2022.04.011","article-title":"Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population","volume":"28","author":"Thorvaldsen","year":"2022","journal-title":"J Card Fail"},{"key":"2026082009500911000_5.1.e002380.7","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurheartj\/ehac544.779","article-title":"SGLT2 inhibitors in real-world patients with heart failure with preserved ejection fraction","volume":"43","author":"Tarantini","year":"2022","journal-title":"Eur Heart J"},{"key":"2026082009500911000_5.1.e002380.8","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.7326\/M21-2392","article-title":"Health Care for Our Nation\u2019s Veterans: A Policy Paper From the American College of Physicians","volume":"174","author":"Crowley","year":"2021","journal-title":"Ann Intern Med"},{"key":"2026082009500911000_5.1.e002380.9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/pds.4918","article-title":"Linking electronic health data in pharmacoepidemiology: Appropriateness and feasibility","volume":"29","author":"Rivera","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026082009500911000_5.1.e002380.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-018-0866-5","article-title":"Development and validation of a heart failure with preserved ejection fraction cohort using electronic medical records","volume":"18","author":"Patel","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"2026082009500911000_5.1.e002380.11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"2026082009500911000_5.1.e002380.12","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v13.i10.585"},{"key":"2026082009500911000_5.1.e002380.13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12116"},{"key":"2026082009500911000_5.1.e002380.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2023.02.001"},{"key":"2026082009500911000_5.1.e002380.15","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/s41591-024-03140-1","article-title":"An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score","volume":"30","author":"Reddy","year":"2024","journal-title":"Nat Med"},{"key":"2026082009500911000_5.1.e002380.16","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/ejhf.2446","article-title":"Revascularization in ischaemic heart failure with preserved ejection fraction: a nationwide cohort study","volume":"24","author":"Deo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026082009500911000_5.1.e002380.17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jtcvs.2021.01.035","article-title":"Outcomes of coronary artery bypass grafting in patients with heart failure with a midrange ejection fraction","volume":"165","author":"Deo","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026082009500911000_5.1.e002380.18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020455","article-title":"Validation of an algorithm to identify heart failure hospitalisations in patients with diabetes within the veterans health administration","volume":"8","author":"Presley","year":"2018","journal-title":"BMJ Open"},{"key":"2026082009500911000_5.1.e002380.19","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.122.009078","article-title":"Validity of International Classification of Diseases (ICD)-10 Diagnosis Codes for Identification of Acute Heart Failure Hospitalization and Heart Failure with Reduced Versus Preserved Ejection Fraction in a National Medicare Sample","volume":"16","author":"Bates","year":"2023","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026082009500911000_5.1.e002380.20","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwp107"},{"key":"2026082009500911000_5.1.e002380.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.02.042"},{"key":"2026082009500911000_5.1.e002380.22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jvs.2019.01.052","article-title":"Why randomized controlled trials do not always reflect reality","volume":"70","author":"Paraskevas","year":"2019","journal-title":"J Vasc Surg"},{"key":"2026082009500911000_5.1.e002380.23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"2026082009500911000_5.1.e002380.24","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/ehf2.14302","article-title":"Long-term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non-cardiac mortality","volume":"10","author":"Shahim","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026082009500911000_5.1.e002380.25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jacasi.2022.11.013","article-title":"Long-Term Outcomes of Heart Failure Patients With Preserved, Mildly Reduced, and Reduced Ejection Fraction","volume":"3","author":"Nagata","year":"2023","journal-title":"JACC Asia"},{"key":"2026082009500911000_5.1.e002380.26","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jamacardio.2020.2028","article-title":"Trends in Readmission and Mortality Rates Following Heart Failure Hospitalization in the Veterans Affairs Health Care System From 2007 to 2017","volume":"5","author":"Parizo","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026082009500911000_5.1.e002380.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684"},{"key":"2026082009500911000_5.1.e002380.28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42078","article-title":"Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis","volume":"5","author":"Bhattarai","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["BMJ Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjmed-2025-002380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:50:20Z","timestamp":1787244620000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjmedicine.bmj.com\/lookup\/doi\/10.1136\/bmjmed-2025-002380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,8,20]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/bmjmed-2025-002380"],"URL":"https:\/\/doi.org\/10.1136\/bmjmed-2025-002380","relation":{},"ISSN":["2754-0413"],"issn-type":[{"value":"2754-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}